logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Betula verrucosa for tree pollen allergy-induced moderate to severe rhinoconjunctivitis

< Back

Betula verrucosa for tree pollen allergy-induced moderate to severe rhinoconjunctivitis

Drugs

Eye Disease, Immunology and Allergy

July 2021


Betula verrucosa is in clinical development for the treatment of adults with confirmed tree pollen allergy-induced moderate to severe rhinoconjunctivitis. Allergic rhinoconjunctivitis is an allergic disorder of the nose and resulting in a chronic, mostly eosinophilic, inflammation of the nasal mucosa and conjunctiva. When the conjunctiva is also involved, the term rhinoconjunctivitis is more accurate. This produces typical symptoms of sneezing, nasal itching, discharge (rhinorrhoea), and congestion.
Betula verrucosa is a sublingual allergy immunotherapy (SLIT) tablet indicated for the treatment of tree pollen allergy, because of its high degree of inhibition of the reaction caused by allergen extracts. As an immunotherapy, betula verrucosa offers the advantage of not just being symptomatic, but also inducing tolerance and so alters the natural course of the disease. If licensed, betula verrucosa will offer an additional treatment option for patients with confirmed tree pollen allergy-induced moderate to severe rhinoconjunctivitis.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts